Nemera is now authorized to handle, assemble, sterilize, and store pharmaceutical drugs and medicinal products for autoinjector combination products at its facility in Neuenburg, Germany.
Nemera received a Pharmaceutical Drug Manufacturing Authorization from the German Government Drug Administration according to the German Drug and Medicinal Product Law for its Neuenburg manufacturing facility in Germany on Sept. 4, the company announced in a Sept. 27, 2017 press release. The certification gives the manufacturing plant the approval to handle, assemble, sterilize, and store pharmaceutical drugs and medicinal products for autoinjectors.
This approval confirms that Nemera meets the highest standards required to ensure the manufacturing and testing of the above-mentioned drug, as well as medicinal and medical products. The pharmaceutical drug manufacturing certification is a required regulatory step to allow Nemera to provide a complete set of services and additional support for the development and manufacturing of pharmaceutical combination products and drug delivery devices.
Nemera currently markets devices in more than 40 countries and operates four facilities in Europe and the United States. Nemera’s services and products include several delivery routes: parenteral (autoinjectors, pens, safety devices, and implanters), ophthalmic (multidose, preservative-free eyedroppers), nasal, buccal, auricular (pumps, valves and actuators for sprays), inhalation (pressurized metered dose inhalers and dry powder inhalers), dermal, and transdermal (airless and atmospheric dispensers).
Source: Nemera
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
2 Commerce Drive
Cranbury, NJ 08512